KASIE PALMER: Open Payments
NPI 1871964676 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,455 in 70 payments from 15 companies in 2025. Trend: 2023 $2,585 · 2024 $2,228 · 2025 $1,455
Food & beverage: $1,446Education: $10
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 18 | $331 |
| ABBVIE INC. | 14 | $235 |
| Regeneron Healthcare Solutions, Inc. | 9 | $225 |
| UCB, Inc. | 10 | $143 |
| Galderma Laboratories, L.P. | 3 | $75 |
| Janssen Biotech, Inc. | 2 | $71 |
| Novartis Pharmaceuticals Corporation | 2 | $63 |
| LEO Pharma Inc. | 2 | $54 |
| Lilly USA, LLC | 2 | $52 |
| Arcutis Biotherapeutics, Inc. | 2 | $48 |
Products named: OPZELURA, DUPIXENT, SKYRIZI, Bimzelx, TREMFYA, COSENTYX, NEMLUVIO, TALTZ.
Industry payments across NV — which companies pay providers there.
